The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 7-11

  Musiał, Kinga ^a   Zwolińska, Danuta ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

CKD; IL 4; MMP 9; sE selectin; TIMP 1

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS LIGAND; GELATINASE A; GELATINASE B; INTERLEUKIN 4; MATRILYSIN; SOLUBLE E SELECTIN; SOLUBLE FAS LIGAND; SOLUBLE FAS PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6; UNCLASSIFIED DRUG; FAS ANTIGEN; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CROSS-SECTIONAL STUDY; METABOLISM; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ANTIGENS, CD95; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84865310400     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.07.025     Document Type: Article

References (30)

1. Nagata, S., Goldstein, P., The Fas death factor. Science 267 (1995), 1449–1456.
2. Stoneman, V.E.A., Bennett, M.R., Role of Fas/FasL in vascular cell apoptosis. J Cardiovasc Pharmacol 53 (2009), 100–108.
3. L inhibits apoptosis and caspase activation. J Vasc Res 44 (2007), 483–494.
4. Clarke, M.C., Figg, N., Maguire, J.J., et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 12 (2006), 1075–1080.
5. McCaffrey, T.A., Du, B., Fu, Ch., et al. The expression of TGF-β receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 31 (1999), 1627–1642.
6. Matter, Ch.M., Chadjichristos, Ch.E., Meier, P., et al. Role for endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation. Circulation 113 (2006), 1879–1887.
7. Geng, Y.J., Henderson, L.E., Levesque, E.B., Muszynski, M., Libby, P., Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17 (1997), 2200–2208.
8. Boyle, J.J., Bowyer, D.E., Weissberg, P.L., Bennett, M.R., Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol 21 (2001), 1402–1407.
9. Blanco-Colio, L.M., Martin-Ventura, J.L., Tunon, J., Garcia-Camarero, T., Berrazueta, J.R., Egido, J., Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease. A novel biomarker of endothelial function?. Atherosclerosis 201 (2008), 407–412.
10. Cardinal, H., Brophy, J.M., Bogaty, P., et al. Usefulness of soluble Fas levels for improving diagnostic accuracy and prognosis for acute coronary syndromes. Am J Cardiol 105 (2010), 797–803.
11. Perianayagam, M.C., Murray, S.L., Balakrishnan, V.S., et al. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure. J Lab Clin Med 136 (2000), 320–327.
12. El-Agroudy, A.E., El-Baz, A., Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients. Clin Exp Nephrol 14 (2010), 152–157.
13. Dalboni, M.A., Sardenberg, C., Andreoli, M.C., et al. Soluble Fas: a novel marker of inflammation in uremia. Artif Organs 27 (2003), 687–691.
14. Kayagaki, N., Kawasaki, A., Ebata, T., et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182 (1995), 1777–1783.
15. Musiał K., Zwolińska, D., Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis 16 (2011), 653–659.
16. Schwartz, G.J., Munoz, A., Schneider, M.F., et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20 (2009), 629–637.
17. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114 (2004), 555–576.
18. Kiener, P.A., Davis, P.M., Rankin, B.M., et al. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 159 (1997), 1594–1598.
19. Jaber, B.L., Perianayagam, M.C., Balakrishnan, V.S., King, A.J., Pereira, B.J., Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system. J Leukoc Biol 69 (2001), 1006–1012.
20. Sata, M., Suhara, T., Walsh, K., Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death. Implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol 20 (2000), 309–316.
21. Musiał K., Zwolińska, D., Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones 16 (2011), 97–103.
22. Cheng, J., Zhou, T., Liu, C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263 (1994), 1759–1762.
23. Wang, T., Dong, Ch., Stevenson, S.C., et al. Overexpression of soluble Fas attenuates transplant arteriosclerosis in rat aortic allografts. Circulation 106 (2002), 1536–1542.
24. Proudfoot, D., Skepper, J.N., Hegyi, L., Bennett, M.R., Shanahan, C.M., Weissberg, P.L., Apoptosis regulates human vascular calcification in vitro. Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87 (2000), 1055–1062.
25. Dalboni, M.A., Cenedeze, M.A., Manfredi, S.R., et al. High serum levels of soluble Fas (sFas) in CKD patients: effects of renal clearance, reabsorption and synthesis. Int J Artif Organs 31 (2008), 405–410.
26. Vargo-Gogola, T., Crawford, H.C., Fingleton, B., Matrisian, L.M., Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 408 (2002), 155–161.
27. Schneider, P., Holler, N., Bodmer, J.L., et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187 (1998), 1205–1213.
28. Tanaka, M., Itai, T., Adachi, M., Nagata, S., Downregulation of Fas ligand by shedding. Nat Med 4 (1998), 31–36.
29. O'Reilly, L.A., Tai, L., Lee, L., et al. Membrane-bound but not secreted Fas ligand is essential for Fas-induced apoptosis and prevention of autoimmunity and cancer. Nature 461 (2009), 659–663.
30. Guo, L.J., Luo, X.H., Xie, H., et al. Tissue inhibitor of matrix metalloproteinase-1 suppresses apoptosis of mouse bone marrow stromal cell line MBA-1. Calcif Tissue Int 78 (2006), 285–292.